{
}
Novo Nordisk reported a strong third quarter, with profits reaching 33.8 billion Danish kroner ($4.88 billion), slightly above forecasts. Sales of its obesity drug Wegovy surged to 17.3 billion kroner ($2.5 billion), contributing to a 44% increase in the obesity care business, leading to a 7% rise in shares.
Novo Nordisk reported mixed Q3 2024 earnings, beating EPS expectations at $0.88 but slightly missing revenue at $10.2 billion. Wegovy sales surged 81% year-over-year to $2.5 billion, while the company tightened its 2024 outlook due to pricing and supply pressures, expecting sales growth of 23%-27%. Despite increased patient numbers, supply constraints for its GLP-1 drugs persist.
Novo Nordisk's Wegovy sales surged 79% to 17.3 billion Danish kroner ($2.5 billion) last quarter, driven by its expansion into new markets. In the US, sales increased by about 50% despite falling prices, as more insurers began covering the drug, providing a boost amid rival Eli Lilly's disappointing obesity sales.
The global veterinary healthcare market is projected to grow from $192.55 billion in 2023 to $270.68 billion by 2028, with a CAGR of 7.0%. Key growth drivers include rising pet ownership, zoonotic disease prevalence, and advancements in telemedicine and genomic medicine. North America remains the largest market, while major players include Zoetis Inc. and Merck & Co.
Novo Nordisk is poised to report its third-quarter earnings, with analysts optimistic about the stock, reflected in six "buy" and five "hold" ratings. The average price target is set at 963.36 Danish krone, approximately 28% above recent levels, driven by anticipated sales growth of its weight-loss drugs, Ozempic and Wegovy. However, increased competition in the weight-loss market could pose challenges, despite analysts noting the company's strong production advantages.
Viking Therapeutics' oral obesity drug has shown promising results, with an average weight loss of about 8% after four weeks at the highest dose, raising expectations among analysts. Despite a 9% drop in shares following the announcement, experts noted the data's potential, comparing it favorably to competitors like Wegovy and Zepbound. Viking plans to initiate a Phase 2 study later this year while advancing its injectable version to Phase 3 trials.
The intratumor cancer therapies market, valued at $151.5 million in 2022, is projected to grow at a CAGR of 9.9% from 2023 to 2030, driven by advances in immunotherapy and personalized medicine. Monoclonal antibodies are leading the technology segment, while lung cancer remains the primary application area. North America is the dominant market, fueled by rising cancer prevalence and increased awareness of innovative treatment options.
Viking Therapeutics Inc. reported promising results for its experimental obesity pill, VK2735, showing that higher doses led to greater weight loss in patients. In an early-stage study, those taking 100-milligram doses lost an average of 8.2% of their body weight over 28 days, compared to 6.8% for the placebo group. This advancement positions Viking to potentially compete with leading treatments from Novo Nordisk and Eli Lilly.
Novo Nordisk plans to seek regulatory approval for semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) after positive Phase 3 trial results. The study showed significant improvements in liver scarring and resolution of MASH among patients receiving semaglutide compared to placebo. Despite the promising findings, analysts remain cautious about its competitive edge in the MASH treatment landscape.
Roche is considering seeking accelerated U.S. approval for its Alzheimer’s drug trontinemab, which shows promise in significantly lowering amyloid protein levels linked to cognitive decline. Early Phase 2 data indicates it may clear amyloid more quickly than competitors, with fewer side effects like ARIA. The company plans to expand its trial to 120 participants while adjusting safety criteria after a related incident.
Eli Lilly and Company
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Novo Nordisk reports strong earnings as Wegovy sales surge in Q3
10:03 06.11.2024
Novo Nordisk reports mixed earnings as Wegovy sales surge amid supply challenges
United States Dollar
Novo Nordisk A/S
Eli Lilly and Company
USA
DNK
Karsten Munk Knudsen
David Ricks
09:00 06.11.2024
wegovy sales surge as international availability expands and us insurers cover costs
07:42 06.11.2024
global veterinary healthcare market projected to reach 270 billion by 2028
United States Dollar
Eli Lilly and Company
Ceva Animal Health LLC
Vetoquinol India Animal Health Pvt Ltd
Merck & Co., Inc.
MSD Animal Health UK Ltd.
IDEXX Laboratories, Inc.
Zoetis Inc.
C.H. Boehringer Sohn AG & Co. KG
National Veterinary Associates Inc.
Phirbo Animal Health
Evonik Industries AG
Boehringer Ingelheim GmbH
Patterson Companies, Inc.
Pets at Home Group Plc
CHN
FRA
RUS
JPN
USA
BRA
KOR
DEU
GBR
IND
IDN
AUS
Show more
02:00 05.11.2024
analysts optimistic on novo nordisk ahead of third quarter earnings report
Danish Krone
United States Dollar
AstraZeneca PLC
Novo Nordisk A/S
Eli Lilly and Company
Viking Therapeutics, Inc.
DNK
Show more
22:16 04.11.2024
viking therapeutics oral obesity drug shows promising early weight loss results
United States Dollar
Hoffmann-La Roche AG
Novo Nordisk A/S
Eli Lilly and Company
Pfizer Inc.
USA
Steven Seedhouse
Roger Song
Thomas Smith
Show more
17:53 04.11.2024
growth of intratumor cancer therapies market driven by innovative treatments and technologies
United States Dollar
Eli Lilly and Company
AbbVie Inc.
AstraZeneca PLC
Amgen Inc.
Novartis AG
Merck & Co., Inc.
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
Bayer AG
USA
Show more
06:23 04.11.2024
viking therapeutics obesity pill shows promising weight loss results in study
02:32 04.11.2024
novo seeks approval for semaglutide as treatment for liver disease
United States Dollar
Eli Lilly and Company
Akero Therapeutics, Inc.
Novo Nordisk A/S
Zealand Pharma A/S
Intercept Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc.
Boehringer Ingelheim KG
89bio, Inc.
DNK
Thomas Smith
Andy Hsieh
Brian Abrahams
Martin Holst Lange
William Blair
Show more
15:45 01.11.2024
Roche considers accelerated approval for promising Alzheimer’s drug trontinemab
United States Dollar
Biogen Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Hoffmann-La Roche AG
CHE
Eli Lilly
Hanno Svoboda
Biogen
Eisai
Show more
22:44 31.10.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Finance Mergers & Acquisitions
Global Financial Events
AI Innovations
Retail and Consumer Goods
Startups & Entrepreneurship
Industry Mergers & Acquisitions
Banking Regulations
Funding Rounds & Investments
Market Analysis and Predictions
Central Bank Actions
Supply Chain Management
AI & Automation Regulations
CEO Changes
Government Policies
Government Economic Policies
Domestic Politics
Global Trade Developments
Countries:
Companies:
NVIDIA Corporation
Huawei Technologies CO. Ltd.
The Goldman Sachs Group, Inc.
Apple Inc.
Tesla, Inc.
Barclays PLC
Citigroup Inc.
Wells Fargo & Company
Morgan Stanley
HSBC HOLDINGS
BNP Paribas SA
American Express Co
DEUTSCHE TELEKOM
Bank of America Corporation
Berkshire Hathaway Inc.
VP Bank AG
Amazon.com, Inc.
Tiktok USD
HSBC Holdings plc
Microsoft Corporation
Currencies:
United States Dollar
Euro
British Pound Sterling
Indian Rupee
Swiss Franc
Chinese Yuan
Japanese Yen
United Arab Emirates Dirham
Offshore Chinese Yuan
Saudi Riyal
Australian Dollar
Hong Kong Dollar
Swedish Krona
Brazilian Real
South Korean Won
Norwegian Krone
Canadian Dollar
Egyptian Pound
People: